Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
ADAddex Therapeutics Ltd logo

Addex Therapeutics Ltd (ADXN)

NASDAQ Capital Market · Currency in USD
$2.97 ▲ +0.08 (+2.69%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.94 ▼ -0.03 (-1.11%)
Pre-market: Oct 26, 6:01 AM ET

Summary

Previous Close
$2.89
Open
$3.00
Day's Range
$2.97 – $3.07
52 Week Range
$2.56 – $10.43
Volume
7,438
Avg. Volume
95,404
Market Cap
$3.66M
Beta (5Y Monthly)
2.02
PE Ratio (TTM)
--
EPS (TTM)
-$4.73
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$30.00

Profile: Addex Therapeutics Ltd

Sector
Healthcare
Industry
Biotechnology
Full-time employees
3
CEO
Timothy Mark Dyer

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction.

Earnings

Next report: Mon, Nov 9, 2026
DateEst.Actual
Sep 28, 2026–-$1.49
Jun 25, 2026–-$1.53
Apr 30, 2026-$1.42-$1.94Miss
Dec 4, 2025–-$1.50
Nov 10, 2025-$1.42-$2.91Miss
Jun 20, 2025-$4.26-$1.33Beat

Analyst view

Consensus price target
$30.00 ▲ +910.1%
Range $30.00 – $30.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ADXN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.